Latest Venous ulcer Stories
Vein specialist Dr. Cindy Asbjornsen of the Vein Healthcare Center in Maine discusses the causes and treatments of spider veins. South Portland, ME (PRWEB) October 24, 2012 Telangiectasia is the technical term, but most people know them as “spider veins.” The tiny red-, blue- or purple-colored veins occur just below the skin but are close enough to be seen on the surface. They may appear as short fine lines, clusters, or in a spider web shape. According to Dr. Cindy Asbjornsen of the...
FORT WORTH, Texas, Sept. 11, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the initiation of a Phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control...
KENNESAW, Ga., Aug. 7, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has closed a clinical trial involving its EpiFix® dehydrated human amniotic membrane allograft for the treatment of diabetic neurovascular foot ulcers. This prospective trial design initially targeted 80 patients. Those patients...
Lawrence LeBlond for redOrbit.com - Your Universe Online A topical spray containing a unique formula of living human cells developed and studied by US and Canadian researchers has been shown to provide a 52 percent greater chance of healing chronic venous leg ulcers than treatment with compression bandages alone. Findings of the study are published in the latest issue of the journal The Lancet. Leg ulcers, painful open wounds that can last for months without proper treatment, are...
FORT WORTH, Texas, Aug. 2, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently under development for the...
FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated...
CHANDLER, Ariz., July 17, 2012 /PRNewswire/ -- Vomaris Innovations, Inc., a leading regenerative medicine company focusing on wound care with bioelectric technology, has been granted another patent (U.S. Pat. No. 8,224,439) related to its bioelectric technology surrounding the use of devices that rely upon reducing and oxidizing agents to treat biologic tissue and promote healing. "Our growing and valuable patent estate is indicative of the powerful momentum behind our leading...
Dr. Cindy Asbjornsen, vein specialist and founder of the Vein Healthcare Center in Maine, will present a free vein health seminar at the Southern Maine Agency on Aging on Wednesday, July 18. South Portland, ME (PRWEB) July 10, 2012 On Wednesday, July 18, Dr. Cindy Asbjornsen of the Vein Healthcare Center in Maine will present a free seminar about vein health at the Southern Maine Agency on Aging in Scarborough, Maine. Dr. Asbjornsen’s seminar “Healthy Legs at Any Age” will review...
Robust evidence exists for some wound care interventions, but there are still gaps in current knowledge requiring international consensus and further high-level clinical evidence, according to a paper published online by BJS, the British Journal of Surgery. Researchers analyzed the findings of 44 Cochrane Systematic Reviews (CSRs) published by the Cochrane Wounds and Peripheral Vascular Disease Groups up to June 2011. The reviews covered CSRs on acute wounds and chronic wounds such as...
FORT WORTH, Texas, June 6, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the company has entered into a distribution agreement with Efe Consultoria & Importacao Ltda to commercialize the OASIS® Extracellular Matrix product line in Brazil. OASIS® products are based on an extracellular matrix material derived from porcine small intestinal submucosa (SIS®), which is designed to support the body's natural healing mechanisms in difficult-to-heal and chronic...
